Mechanisms of Disease: the complement system in renal injury—new ways of looking at an old foe

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Nature Clinical Practice Nephrology

• Publication date

  2007-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/ncpneph0465PMID 17457361
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II).

  2006cited by this paper
• Identification of the target self-antigens in reperfusion injury

  2006cited by this paper
• Influence of donor C3 allotype on late renal-transplantation outcome.

  2006cited by this paper
• CD46 (Membrane Cofactor Protein) Acts as a Human Epithelial Cell Receptor for Internalization of Opsonized Uropathogenic Escherichia coli1

  2006cited by this paper
• Accumulation of immune complexes in glomerular disease is independent of locally synthesized c3.

  2006cited by this paper
• Strategies of therapeutic complement inhibition.

  2006cited by this paper
• Favorable Long‐Term Outcome after Liver‐Kidney Transplant for Recurrent Hemolytic Uremic Syndrome Associated with a Factor H Mutation

  2006cited by this paper
• Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome.

  2006cited by this paper
• Prevalence and clinico-serological correlations of anti-alpha-enolase, anti-C1q, and anti-dsDNA antibodies in patients with systemic lupus erythematosus.

  2006cited by this paper
• Local extravascular pool of C3 is a determinant of postischemic acute renal failure

  2006cited by this paper
• Complement Activation Contributes to Both Glomerular and Tubulointerstitial Damage in Adriamycin Nephropathy in Mice1

  2006cited by this paper
• Complement deficient mice as model systems for kidney diseases

  2006cited by this paper
• A randomized, placebo-controlled trial of complement inhibition in ischemia-reperfusion injury after lung transplantation in human beings.

  2005cited by this paper
• Signaling through Up-Regulated C3a Receptor Is Key to the Development of Experimental Lupus Nephritis1

  2005cited by this paper
• Association Between Mannose‐Binding Lectin Levels and Graft Survival in Kidney Transplantation

  2005cited by this paper
• Binding of complement factor H to endothelial cells is mediated by the carboxy-terminal glycosaminoglycan binding site.

  2005cited by this paper
• Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome.

  2005cited by this paper
• C3 is central to the interstitial component of experimental immune complex glomerulonephritis.

  2005cited by this paper
• C5a promotes development of experimental lupus nephritis which can be blocked with a specific receptor antagonist

  2005cited by this paper
• Membranoproliferative glomerulonephritis type II (dense deposit disease): an update.

  2005cited by this paper
• Factor H and atypical hemolytic uremic syndrome: mutations in the C-terminus cause structural changes and defective recognition functions.

  2005cited by this paper
• Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome.

  2005cited by this paper
• Genetic abnormalities of complement regulators in hemolytic uremic syndrome: how do they affect patient management?

  2005cited by this paper
• Complement Inhibitors Targeted to the Proximal Tubule Prevent Injury in Experimental Nephrotic Syndrome and Demonstrate a Key Role for C5b-91

  2005cited by this paper
• The mannose-binding lectin-pathway is involved in complement activation in the course of renal ischemia-reperfusion injury.

  2004cited by this paper
• Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes.

  2004cited by this paper
• Complement and complement regulatory proteins as potential molecular targets for vascular diseases.

  2004cited by this paper
• Non-enteropathic hemolytic uremic syndrome: causes and short-term course.

  2004cited by this paper
• The complement system in regulation of adaptive immunity

  2004cited by this paper
• Anti‐C1q autoantibodies in murine lupus nephritis

  2004cited by this paper
• Glycation inactivation of the complement regulatory protein CD59: a possible role in the pathogenesis of the vascular complications of human diabetes.

  2004cited by this paper
• Independent pathways of P-selectin and complement-mediated renal ischemia/reperfusion injury.

  2004cited by this paper
• Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome

  2004cited by this paper
• The role of complement in the development of systemic lupus erythematosus.

  2004cited by this paper
• Opsonization with C1q and Mannose-Binding Lectin Targets Apoptotic Cells to Dendritic Cells1

  2004cited by this paper
• The human complement factor H: functional roles, genetic variations and disease associations.

  2004cited by this paper
• Pharmacokinetics and safety of TP10, soluble complement receptor 1, in infants undergoing cardiopulmonary bypass.

  2004cited by this paper
• Effect of Pexelizumab, an Anti-C5 Complement Antibody, as Adjunctive Therapy to Fibrinolysis in Acute Myocardial Infarction: The COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) Trial

  2003cited by this paper
• Pexelizumab, an Anti-C5 Complement Antibody, as Adjunctive Therapy to Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction: The COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) Trial

  2003cited by this paper
• Administration of a soluble recombinant complement C3 inhibitor protects against renal disease in MRL/lpr mice.

  2003cited by this paper
• Familial haemolytic uraemic syndrome and an MCP mutation.

  2003cited by this paper
• Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome.

  2003cited by this paper
• Antibody‐Mediated Rejection Criteria – an Addition to the Banff ′97 Classification of Renal Allograft Rejection

  2003cited by this paper
• Autoantibodies against mannose‐binding lectin in systemic lupus erythematosus

  2003cited by this paper
• Mannose‐binding lectin engagement with late apoptotic and necrotic cells

  2003cited by this paper
• Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome

  2003cited by this paper
• Successful treatment of factor H-related haemolytic uraemic syndrome.

  2002cited by this paper
• Transgenic Expression of a Soluble Complement Inhibitor Protects Against Renal Disease and Promotes Survival in MRL/lpr Mice1

  2002cited by this paper
• Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury.

  2002cited by this paper
• Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H

  2002cited by this paper
• Tortuosity of the White Matter Medullary Arterioles Is Related to the Severity of Hypertension

  2002cited by this paper
• C5a is important in the tubulointerstitial component of experimental immune complex glomerulonephritis

  2002cited by this paper
• C6 mediates chronic progression of tubulointerstitial damage in rats with remnant kidneys.

  2002cited by this paper
• Local synthesis of complement component C3 regulates acute renal transplant rejection

  2002cited by this paper
• C4d deposition in acute rejection: an independent long-term prognostic factor.

  2002cited by this paper
• Epithelial secretion of C3 promotes colonization of the upper urinary tract by Escherichia coli

  2001cited by this paper
• Membrane-targeted complement inhibitors.

  2001cited by this paper
• Complement. First of two parts.

  2001cited by this paper
• Complement. Second of two parts.

  2001cited by this paper
• Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries.

  2001cited by this paper
• Association of mannose-binding lectin gene variation with disease severity and infections in a population-based cohort of systemic lupus erythematosus patients

  2001cited by this paper
• A Hierarchical Role for Classical Pathway Complement Proteins in the Clearance of Apoptotic Cells in Vivo

  2000cited by this paper
• Predominant role for C5b-9 in renal ischemia/reperfusion injury.

  2000cited by this paper
• Phase I trial of the recombinant soluble complement receptor 1 in acute lung injury and acute respiratory distress syndrome

  2000cited by this paper
• Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass.

  1999cited by this paper
• Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: role of factor H abnormalities. Italian Registry of Familial and Recurrent Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura.

  1999cited by this paper
• Complement membrane attack complex (C5b-9) mediates interstitial disease in experimental nephrotic syndrome.

  1999cited by this paper
• Cutting edge: C1q protects against the development of glomerulonephritis independently of C3 activation.

  1999cited by this paper
• Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries.

  1999cited by this paper
• Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies

  1998cited by this paper
• Complement activation products in the urine from proteinuric patients.

  1998cited by this paper
• Contribution of renal secreted complement C3 to the circulating pool in humans.

  1998cited by this paper
• Genetic studies into inherited and sporadic hemolytic uremic syndrome.

  1998cited by this paper
• Role of complement in acute tubulointerstitial injury of rats with aminonucleoside nephrosis.

  1997cited by this paper
• The role of complement in the pathogenesis of tubulointerstitial lesions in rat mesangial proliferative glomerulonephritis.

  1997cited by this paper
• Three new polymorphisms in the human complement factor H gene and promoter region

  1997cited by this paper
• Membrane attack complex and membrane cofactor protein are related to tubulointerstitial inflammation in various human glomerulopathies.

  1997cited by this paper
• Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiency.

  1995cited by this paper
• Localization of the complement regulatory proteins in the normal human kidney.

  1994cited by this paper
• Capillary deposition of C4d complement fragment and early renal graft loss.

  1993cited by this paper
• The consequences for renal function of widening of the interstitium and changes in the tubular epithelium of the renal cortex and outer medulla in various renal diseases.

  1992cited by this paper
• Vascular deposition of complement‐split products in kidney allografts with cell‐mediated rejection

  1991cited by this paper
• Increased ammoniagenesis as a determinant of progressive renal injury.

  1991cited by this paper
• Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis.

  1990cited by this paper
• In vitro alternative pathway activation of complement by the brush border of proximal tubules of normal rat kidney.

  1982cited by this paper
• HÆMOLYTIC-URÆMIC SYNDROME: EVIDENCE FOR INTRAVASCULAR C3 ACTIVATION

  1974cited by this paper
• Letter: Speaking aid.

  1974cited by this paper
• Letter: Haemolytic-uraemic syndrome: evidence for intravascular C3 activation.

  1974cited by this paper
• [Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia].

  1955cited by this paper
• J Am Soc Nephrol 13: 242–251, 2002 Detection of the Complement Degradation Product C4d in Renal Allografts: Diagnostic and Therapeutic Implications

  year unknowncited by this paper

• Association of Urinary Complement Peptides with Kidney Function and Progression of Kidney Disease.

  2026cites this paper
• Molecular insights into chronic glomerulonephritis and dopamine interplay.

  2025cites this paper
• Characteristics of glomerulonephritis with dominant C1q precipitation compared to corresponding glomerulonephritis without C1q staining on immunofluorescent examination

  2024cites this paper
• Inhibition of colon C5a/C5a receptor signalling pathway confers protection against LPS-induced acute kidney injury via gut microbiota-kidney axis.

  2024cites this paper
• Immunology of Kidney Disease.

  2024cites this paper
• The importance of sialic acid, pH and ion concentration on the interaction of uromodulin and complement factor H

  2021cites this paper
• C1q nephropathy in a young female sensitive to low-dose steroid: Clinicopathological correlation and outcome a rare clinical scenario

  2019cites this paper
• Endothelial Microparticles and Systemic Complement Activation in Patients With Chronic Kidney Disease

  2018cites this paper
• Complement analysis 2016: Clinical indications, laboratory diagnostics and quality control.

  2016cites this paper
• Differential Ly6C Expression after Renal Ischemia-Reperfusion Identifies Unique Macrophage Populations.

  2016cites this paper
• Complement Pathway Associated Glomerulopathies

  2016cites this paper
• Clinical Significance of Complement Abnormalities

  2016cites this paper
• The Role of Complement in Disease

  2016cites this paper
• Réanimation des patients d’onco-hématologie : nouvelles thérapeutiques, nouvelles complications, nouveaux contrats d’admission

  2015cites this paper
• Complement-Coagulation Cross-Talk: A Potential Mediator of the Physiological Activation of Complement by Low pH

  2015cites this paper
• [Critical care of Onco-hematology patients: new therapeutic targets, new complications and new admission policies].

  2015cites this paper
• Complement Activation: The role in Health and Disease and Strategies of Therapeutic Complement Inhibition

  2014cites this paper
• Tissue-specific deletion of Crry from mouse proximal tubular epithelial cells increases susceptibility to renal ischemia reperfusion injury

  2014cites this paper
• C3a Receptor Antagonist Ameliorates Inflammatory and Fibrotic Signals in Type 2 Diabetic Nephropathy by Suppressing the Activation of TGF-β/smad3 and IKBα Pathway

  2014cites this paper
• Diverse Clinical and Histology Presentation in C1q Nephropathy

  2013cites this paper
• Progress and Trends in Complement Therapeutics.

  2013cites this paper
• C1q nephropathy- unity in diversity

  2013cites this paper
• Immunological and Molecular Mechanisms Leading to Fibrosis: Origin of Renal Myofibroblasts

  2012cites this paper
• Biological markers of nephrotic syndrome: a few steps forward in the long way.

  2012cites this paper
• Approach to the Patient with Kidney Disease

  2012cites this paper
• Membranous nephropathy.

  2011cites this paper
• Complement - known and unknown facts

  2011cites this paper
• Membranous nephropathy: From mechanisms to therapies

  2010cites this paper
• Discovering hidden relationships between renal diseases and regulated genes through 3D network visualizations

  2010cites this paper
• Thrombin Inhibition During Kidney Ischemia-Reperfusion Reduces Chronic Graft Inflammation and Tubular Atrophy

  2010cites this paper
• Eculizumab in atypical hemolytic-uremic syndrome

  2009cites this paper
• Anaphylatoxin C5a contributes to the pathogenesis of cisplatin-induced nephrotoxicity.

  2009cites this paper
• Eculizumab for atypical hemolytic-uremic syndrome.

  2009cites this paper
• Current status and issues of C1q nephropathy

  2009cites this paper
• The Role of Extracellular DNA in Autoimmunity in SLE

  2009cites this paper
• Complement: coming full circle

  2009influential citation
• Expression of the Decay-Accelerating Factor (CD55) in Renal Transplants—A Possible Prediction Marker of Allograft Survival

  2009cites this paper
• Resveratrol attenuates C5a‐induced inflammatory responses in vitro and in vivo by inhibiting phospholipase D and sphingosine kinase activities

  2009cites this paper
• Anaphylatoxin C 5 a contributes to the pathogenesis of cisplatin-induced nephrotoxicity

  2009cites this paper
• Anticomplement therapy

  2008cites this paper
• Complement, roles in renal disease and modulation for therapy.

  2008cites this paper
• Contribution of Complement Activation on Kidney Injury

  2008cites this paper
• Granulin‐epithelin precursor as a therapeutic target for hepatocellular carcinoma

  2008cites this paper
• Complement and the atypical hemolytic uremic syndrome in children

  2008cites this paper
• Complement in glomerular injury

  2007cites this paper